SHIOU-HWA JEELI-FANG WANG2018-09-102018-09-102007http://www.scopus.com/inward/record.url?eid=2-s2.0-40749105321&partnerID=MN8TOARShttp://scholars.lib.ntu.edu.tw/handle/123456789/334164Atopic dermatitis is a chronically relapsing eczematous disease of the skin. A wide range of therapeutic regimens has been used for atopic dermatitis. A better understanding of its pathogenesis will also lead to the development of novel approaches to treating this disease. This article reviews the recent advances in allergen-specific sublingual immunotherapy and therapy with antileukotriene drugs, probiotics, mycophenolate mofetil, leflunomide, and intermittent fluticasone propionate ointment, which the authors expect will be clinically useful therapies in the near future. ? 2007 Humana Press Inc.Atopic dermatitis; Fluticasone propionate; Leflunomide; Leukotriene antagonists; Mycophenolate mofetil; Probiotic; Sublingual immunotherapy[SDGs]SDG3azathioprine; corticosteroid; cyclosporin; fluticasone propionate; glucocorticoid; hydrocortisone; hydrocortisone butyrate; immunomodulating agent; leflunomide; leukotriene receptor blocking agent; montelukast; mycophenolic acid 2 morpholinoethyl ester; pranlukast; probiotic agent; zafirlukast; zileuton; asthma; atopic dermatitis; clinical trial; disease association; disease severity; drug effect; drug efficacy; drug mechanism; drug tolerability; human; maintenance therapy; milk allergy; review; unspecified side effect; Androstadienes; Animals; Dermatitis, Atopic; Desensitization, Immunologic; Histamine H1 Antagonists; Humans; Immunosuppressive Agents; Isoxazoles; Leukotriene Antagonists; Mycophenolic Acid; T-Lymphocytes, Regulatoryjournal article10.1007/s12016-007-0043-6